Clinical trials: Anemia Associated With Chronic Kidney Disease (CKD)
- Condition Anemia Associated With Chronic Kidney Disease (CKD)
- Funder type Industry (pharma, biotech, devices)
Anemia, Chronic Renal Insufficiency
Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)
This is an open-label, single-arm, baseline-controlled, multicenter efficacy and safety switch study involving 500 CKD subjects suffering from anemia and treated previously with a stable dose of ESA s.c.
- Trial name
- SWEEP (NCT00869856)
- Testing
- HX575 solution for s.c. administration
- Where
- 19 sites in Bulgaria, France and 3 more
- Sponsor
- Sandoz
Anaemia
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in approximately 68 subjects with anemia…
- Trial name
- NCT01587898
- Testing
- GSK1278863
- Where
- 55 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Anemia; Hemodialysis Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
For hemodialysis subjects currently receiving ESAs with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548.
- Trial name
- NCT03439137
- Testing
- MT-6548, Darbepoetin alfa
- Where
- 28 sites in Japan
- Volunteers
- 323 people
- Sponsor
- Tanabe Pharma Corporation
Anaemia
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
This is an international, multicenter trial, evaluating pharmacokinetics (PK) (4 weeks), safety (52 weeks), and hemoglobin (Hgb) response (52 weeks) to daprodustat in children and adolescent participants with anemia associated…
- Trial name
- ASCEND-P (NCT05682326)
- Testing
- Daprodustat
- Where
- 4 sites in Japan, South Korea
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Anemia; Hemodialysis Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
For hemodialysis subjects not receiving ESAs with anemia associated with chronic kidney disease, evaluate Hb correction and maintenance effect and safety of MT-6548.
- Trial name
- NCT03461146
- Testing
- MT-6548
- Where
- 16 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Tanabe Pharma Corporation
Anemia, Anaemia
Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia
The study will evaluate the ability of GSK1278863 to increase the hemoglobin (Hgb) concentration, or maintain it within the target range, and the safety and efficacy of GSK1278863 over 16 weeks of treatment, in…
- Trial name
- NCT02075463
- Testing
- GSK1278863
- Where
- 10 sites in United States
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Renal Anemia Associated With Chronic Renal Failure (CRF)
A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug
This study is to evaluate safety and efficacy of intermittent oral dosing of ASP1517 in dialysis chronic kidney disease patients with anemia.
- Trial name
- NCT01888445
- Testing
- roxadustat, darbepoetin alfa
- Where
- 8 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Astellas Pharma Inc
Anaemia
Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
This study is intended to evaluate the dose-response relationship of GSK1278863 over the first 4 weeks of treatment and evaluate the safety and efficacy of GSK1278863 over 24 weeks to maintain hemoglobin (Hgb) level in…
- Trial name
- NCT01977482
- Testing
- GSK1278863, rhEPO
- Where
- 107 sites in United States, Australia and 14 more
- Volunteers
- 216 people
- Sponsor
- GlaxoSmithKline
Anaemia
A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
This study is to evaluate the efficacy and safety of QLG1218(daprodustat) following a switch from erythropoiesis-stimulating agent (ESA) in Chinese HD subjects with renal anemia who are currently treated with ESA.
- Trial name
- NCT07300111
- Testing
- Daprodustat, Darbepoetin alfa
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Anaemia
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)
This will be an open-label, randomized, parallel-group study in hemodialysis-dependent (HD) participants with anemia associated with chronic kidney disease (CKD), designed to compare the effects of daprodustat to epoetin alfa on…
- Trial name
- NCT03029247
- Testing
- Daprodustat, Epoetin alfa
- Where
- 11 sites in United States
- Volunteers
- 105 people
- Sponsor
- GlaxoSmithKline
Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
To evaluate the efficacy and safety of MT-6548 in peritoneal dialysis subjects with anemia associated with chronic kidney disease
- Trial name
- NCT03402386
- Testing
- MT-6548
- Where
- 17 sites in Japan
- Volunteers
- 42 people
- Sponsor
- Tanabe Pharma Corporation
Anemia of Chronic Kidney Disease
To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
This study is to evaluate 24-week efficacy and 52 week immunogenicity of subcutaneous Eporon versus Epoetin Alfa (Eprex) in the treatment of anemia associated with chronic renal failure in pre-dialysis patients.
- Trial name
- NCT03521713
- Testing
- EPORON, EPREX
- Where
- Turkey (Türkiye)
- Volunteers
- 214 people
- Sponsor
- Dong-A ST Co., Ltd.
Anaemia
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
The purpose of this multi-center study in non-dialysis participants with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.
- Trial name
- NCT03409107
- Testing
- Daprodustat (GSK1278863), Iron therapy
- Where
- 168 sites in United States, Argentina and 12 more
- Volunteers
- 614 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease Associated Anemia
A Non-interventional, Epidemiological, Registry-based Evaluation of Anaemia in Swedish Patients With Chronic Kidney Disease
The primary purpose of this study is to describe renal anemia treatment patterns in non-dialysis dependent (ND) and dialysis dependent (DD) populations, with a particular focus on iron use in erythropoiesis stimulating agent…
- Trial name
- ASK (NCT03643601)
- Testing
- Non-Interventional
- Where
- Sweden
- Volunteers
- 14,415 people
- Sponsor
- Astellas Pharma a/s
Anemia; Non-dialysis Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
For Non-dialysis subjects with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548.
- Trial name
- NCT03329196
- Testing
- MT-6548, Darbepoetin alfa
- Where
- 31 sites in Japan
- Volunteers
- 304 people
- Sponsor
- Tanabe Pharma Corporation
Anemia
An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease
The purpose of this study is to demonstrate that once weekly and once every-2-weeks treatment with epoetin alfa, in patients with anemia associated with chronic kidney disease, is not less effective than the approved treatment…
- Trial name
- NCT00440557
- Testing
- Epoetin alfa 3 times weekly /once weekly, Epoetin alfa once weekly, Epoetin alfa once every two weeks
- Where
- 62 sites in United States, Puerto Rico
- Volunteers
- 375 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Kidney Disease
HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
The study will assess the immunogenicity, safety, and efficacy of HX575 epoetin alfa administered subcutaneously (s.c.) in patients suffering from anemia due to chronic kidney disease (CKD)
- Trial name
- SENSE (NCT01576341)
- Testing
- HX575 epoetin alfa (Sandoz)
- Where
- 50 sites in Germany, Italy and 5 more
- Volunteers
- 417 people
- Sponsor
- Sandoz
Anemia Associated With Chronic Kidney Disease
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
This study will be conducted to assess the pharmacokinetics of vadadustat 600, 750, and 900 milligrams daily, and intravenous erythropoiesis-stimulating agent (darbepoetin alfa or epoetin alfa), in hemodialysis participants with…
- Trial name
- NCT03992066
- Testing
- Vadadustat, Darbepoetin alfa, Epoetin alfa
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- Akebia Therapeutics
Anaemia
Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Daprodustat administration has the potential, by virtue of increasing hypoxia-inducible factor (HIF) levels, to increase oral iron absorption and incorporation into hemoglobin (Hgb).
- Trial name
- NCT03457701
- Testing
- Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Anaemia
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
- Trial name
- NCT02876835
- Testing
- Daprodustat, Darbepoetin alfa, Iron Therapy
- Where
- 574 sites in United States, Argentina and 37 more
- Volunteers
- 3,872 people
- Sponsor
- GlaxoSmithKline